Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer RecurrenceJAMA NETWORK OPENIF9.72022-01-269OAAI
Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo FrameworkCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-07-2936OAAI
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk StratificationEUROPEAN UROLOGY OPEN SCIENCEIF4.52020-10-0114OAAI
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer CellsMOLECULAR CANCER RESEARCHIF4.72019-11-0122OAAI
Potential systemic effects of beta-blocker use in prostate cancer patientsCANCER RESEARCHIF16.62018-08-140PRE
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy (vol 117, pg 1656, 2017)BRITISH JOURNAL OF CANCERIF6.82018-02-203OAAI
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomyBRITISH JOURNAL OF CANCERIF6.82017-10-0335OA
PBX3 is a putative biomarker of aggressive prostate cancerPBX3是侵袭性前列腺癌的推定生物标志物INTERNATIONAL JOURNAL OF CANCERIF4.72016-06-2544OAAI
Association Between Use of β-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic DiseaseEUROPEAN UROLOGYIF25.22014-03-01188PREAI
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's Letter to the Editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fossa, Kristin Austlid Tasken. Association Between Use of β-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007EUROPEAN UROLOGYIF25.22013-07-0110PREAI